BioNTech logo

BioNTech

BNTX | NASDAQ
Chart Builder DCF Calculator
$85.26
-$0.34 (-0.40%)
At close: Nov 16, 2026, 4:00 PM ET
$86.45
+$1.19 (+1.40%)
After-hours: Nov 16, 2026, 7:44 PM ET
-0.40%

Rating

Updated: Nov 16, 2026
30.6
Fundamentals Weak
Market Sentiment Neutral
Moat Narrow
Sector Rank #781/1021 (Top 76%)

Key Statistics

Market Data

Market Cap $21.14B
1D Range
85.20 87.00
52W Range
83.89 119.34

Valuation (TTM)

PE -10.86
PB 1.05
EV/EBITDA -9.37

Valuation (NTM)

Forward PE N/A
Forward PEG -0.20
Price Target $114.00
Loading financial charts...

Profile

BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline in...

Sector Healthcare
Industry Biotechnology
Employees 7,807
IPO Date Oct 10, 2019
Fiscal Year January - December

Latest News

BioNTech May Be the Next Moderna. Even if it Isn't, the Stock Is a Buy.

4 days ago · barrons.com

BioNTech May Be the Next Moderna. Even if it Isn't, the Stock Is a Buy.
BioNTech vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?

5 days ago · fool.com

BioNTech vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy for 2027?
BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era.

8 days ago · fool.com

BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era.
Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher

11 days ago · 247wallst.com

Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher
Axsome Therapeutics vs. BioNTech: Which Healthcare Stock Is a Better Buy for 2027?

12 days ago · fool.com

Axsome Therapeutics vs. BioNTech: Which Healthcare Stock Is a Better Buy for 2027?
BioNTech Q3: Bristol Myers Revenue Masks A Narrowing Oncology Bet (Rating Downgrade)

13 days ago · seekingalpha.com

BioNTech Q3: Bristol Myers Revenue Masks A Narrowing Oncology Bet (Rating Downgrade)
BioNTech SE (BNTX) Q3 2026 Earnings Call Transcript

13 days ago · seekingalpha.com

BioNTech SE (BNTX) Q3 2026 Earnings Call Transcript
BioNTech Q3 Earnings Call Highlights

14 days ago · marketbeat.com

BioNTech Q3 Earnings Call Highlights
BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update

14 days ago · globenewswire.com

BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher

20 days ago · 247wallst.com

Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher

Earnings

Latest Earnings
Nov 3, 2026
EPS
$0.83
Beat +9.25%
REV
$1.46B
Beat +24.84%
Next Earnings
Mar 9, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
11
Consensus
Buy
Price Target
$114.00
Upside
+33.71%
Buy (9)
Hold (2)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.